Erasca, Inc. (ERAS): Price and Financial Metrics
ERAS Price/Volume Stats
| Current price | $1.93 | 52-week high | $9.25 |
| Prev. close | $1.97 | 52-week low | $1.88 |
| Day low | $1.88 | Volume | 1,564,300 |
| Day high | $1.98 | Avg. volume | 791,010 |
| 50-day MA | $2.51 | Dividend yield | N/A |
| 200-day MA | $3.09 | Market Cap | 291.51M |
ERAS Stock Price Chart Interactive Chart >
Erasca, Inc. (ERAS) Company Bio
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.
Latest ERAS News From Around the Web
Below are the latest news stories about ERASCA INC that investors may wish to consider to help them evaluate ERAS as an investment opportunity.
Erasca to Present at the Cantor Global Healthcare ConferenceSAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in a fireside chat on Tuesday, September 26, 2023, at 8:10 am Eastern Time at the Cantor Global Healthcare Conference, which is being held at the InterContinental New York Barclay in New York, New York. M |
Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceSAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in a fireside chat on Tuesday, September 12, 2023, at 5:30 pm Eastern Time at the Morgan Stanley 21st Annual Global Healthcare Conference, which is being held at the Sheraton New York Hotel in New York, N |
Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid TumorsAnti-tumor activity in patients with NRAS Q61X melanoma and KRAS Q61X NSCLC supports tissue agnostic development in RAS Q61X solid tumors Initial Phase 1b combination data from SEACRAFT-1 expected in Q2-Q4 2024 Dosing of first patient in pivotal SEACRAFT-2 trial in NRAS-mutant melanoma expected in H1 2024 SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapie |
Erasca Reports Second Quarter 2023 Financial Results and Business UpdatesSignificant progress across all clinical programs including Phase 1b combo data for ERAS-007 and ERAS-601, FTD and ODD granted for ERAS-801, and publication of naporafenib combination data Multiple meaningful clinical catalysts over the next 18 months and beyond Strong balance sheet with cash, cash equivalents, and marketable securities of $365 million as of June 30, 2023, expected to fund operations into H2 2025 SAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinica |
Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
ERAS Price Returns
| 1-mo | -25.48% |
| 3-mo | -30.82% |
| 6-mo | -35.67% |
| 1-year | -76.14% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -55.22% |
| 2022 | -72.34% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...